Magnesium Sulfate For Brain Injury
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of the study is to determine whether magnesium sulfate, given within 8 hours of a moderate or severe traumatic brain injury improves survival, decreases the number of people developing seizures, improves the survivors' mental and psychological functioning, including the ability to return to daily life, live independently, and return to work or school.
| Condition | Intervention | Phase |
|---|---|---|
|
Brain Injuries Head Injury Brain Concussion |
Drug: magnesium sulfate |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | Magnesium Sulfate for Neuroprotection After Brain Trauma |
| Study Start Date: | August 1998 |
| Study Completion Date: | May 2005 |
| Primary Completion Date: | May 2005 (Final data collection date for primary outcome measure) |
The purpose of the study is to determine if treating head-injured patients with magnesium sulfate will improve medical, mental, and psychological recovery. In particular, the study will assess each patient's ability to return to daily life, live independently, and return to work or school as done before the head injury occurred. The study will also assess magnesium sulfate's ability to reduce the risk of developing seizures (epilepsy) as well as to improve survival rates after a traumatic brain injury. Patients on the study are assigned randomly (by chance) to either the magnesium sulfate group or the group which gets a placebo. This means they have an equal chance of being in either group. Before the first dose is given, two teaspoons worth of blood are drawn from a vein in the arm. The first dose of magnesium sulfate is 1meq/kg given intravenously within 8 hours of injury. Then a five day continuous intravenous infusion of magnesium sulfate 0.24meq/kg per hour is begun. Daily magnesium levels are checked and the dose changed in order to keep the Magnesium blood level at approximately 4meq/L. If the person does not receive magnesium sulfate, he receives a placebo which looks just like magnesium sulfate but contains no active medication. If the person leaves the hospital before the five days are over, the magnesium or placebo is stopped. Patients on the study will receive a brief exam in person or over the phone at one and three months after the injury to determine whether they have had any seizures and to evaluate how they are functioning and recovering from their head injury. Each evaluation will last about one hour. At six months after the injury, they will have full neuropsychological and psychosocial evaluations done at Harborview. These tests will take about five hours to complete and include tests of vocabulary, problem solving, and coordination. There will be questions about how the injury has affected the way they feel and interact socially. For example, there will be questions about their ability to work, manage personal affairs, what their moods are like, and how anger is handled.
Eligibility| Ages Eligible for Study: | 14 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Traumatic brain injury with post-resuscitation Glasgow Coma Scale of 3-12 or, if intubated, motor score of 1-5, or who require emergent neurosurgical intervention precluding the accurate assessment of Glasgow Coma Scale.
Exclusion Criteria:
- Injury greater than 8 hours old
- Age under 14 years
- Compromised renal function (creatinine of 2.0 mb/dl or greater)
- Membership in a vulnerable population (e.g. pregnant woman, prisoner, etc.)
- Residence making follow-up unlikely (e.g. lives outside U.S.)
- Refusal to participate
Contacts and Locations| United States, Washington | |
| University of Washington | |
| Seattle, Washington, United States, 98104 | |
| Principal Investigator: | Nancy Temkin, Ph.D. | University of Washington |
More Information
Publications:
| Responsible Party: | Nancy Temkin, Professor, University of Washington |
| ClinicalTrials.gov Identifier: | NCT00004730 History of Changes |
| Obsolete Identifiers: | NCT00004484 |
| Other Study ID Numbers: | R01NS19643 |
| Study First Received: | February 25, 2000 |
| Last Updated: | October 26, 2011 |
| Health Authority: | United States: Federal Government |
Keywords provided by University of Washington:
|
head injury traumatic brain injury concussion magnesium sulfate neuroprotection |
Additional relevant MeSH terms:
|
Brain Concussion Craniocerebral Trauma Brain Injuries Brain Diseases Central Nervous System Diseases Nervous System Diseases Trauma, Nervous System Head Injuries, Closed Wounds and Injuries Wounds, Nonpenetrating Magnesium Sulfate Analgesics Sensory System Agents Peripheral Nervous System Agents |
Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Anesthetics Central Nervous System Depressants Anti-Arrhythmia Agents Cardiovascular Agents Anticonvulsants Calcium Channel Blockers Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Tocolytic Agents Reproductive Control Agents |
ClinicalTrials.gov processed this record on May 23, 2013